Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder (Q42661974)

4 November 2017

title

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

4 November 2017

main subject

1 reference

Robert L Findling

1 reference

4 November 2017

Ann C Childress

0 references

author name string

Suma Krishnan

series ordinal

1 reference

4 November 2017

James J McGough

series ordinal

1 reference

4 November 2017

language of work or name

1 reference

1 July 2008

1 reference

4 November 2017

1 reference

4 November 2017

1 reference

4 November 2017

1 reference

4 November 2017

page(s)

614-620

1 reference

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900016898

7 January 2021

10.1017/S1092852900016898

Identifiers

DOI

0 references

1 reference